Covera Health, a leader in AI-driven radiology performance measurement and patient care, has announced results from its analysis of downstream healthcare spending for patients using Covera-designated high-quality imaging facilities.

The study found that patients receiving high-tech imaging at these facilities saw a reduction of up to $2,487, or 12%, in their combined 12-month medical and pharmacy claims costs.

This analysis compared a matched control group using non-Covera-designated facilities over three years, utilizing historical medical and pharmacy claims data from Covera’s patient population across much of the United States.

Covera’s designation process aims to minimize misdiagnoses during the diagnostic phase, thereby enhancing health outcomes, lowering unnecessary healthcare expenses, and avoiding complications in downstream care.

The analysis indicated that patients undergoing high-tech imaging (CT, MRI) at Covera-designated facilities experienced 6% to 12% lower downstream costs, including imaging and post-imaging expenses, compared to the matched control group.

This cost reduction was mainly due to fewer hospital admissions, emergency department visits, and outpatient services.

The outdated view of radiology as just another healthcare commodity is risky. At Covera, we are not just challenging this perception.

Dismantling it by proving that high-quality radiology care is crucial for patient outcomes and a significant factor in reducing downstream healthcare costs.

The financial impact estimation methodology of Covera’s program was reviewed by Milliman, Inc., a leading global consulting and actuarial firm.
 

Source: prnewswire.com

Report Abuse